APYX vs DERM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
APYX exhibits a weak Piotroski F-Score of 1/9, signaling significant financial distress and poor operational health, with negative ROE, ROA, and high debt/equity. Despite this, the company demonstrates strong revenue growth (34.7% YoY) and a compelling earnings surprise history, with recent quarters beating estimates by an average of 33.74%. The stock is trading at a premium valuation (Price/Book: 10.43, Price/Sales: 2.82) but is supported by a strong analyst consensus of 'strong_buy' and a target price of $6.40, implying significant upside. Insider activity remains neutral, but the recent 1-year return of +249% reflects strong market momentum. The absence of a Graham Number and Altman Z-Score limits fundamental safety checks, but growth expectations appear to justify the valuation premium.
DERM shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 0/9). Concerns include weak profitability or high valuation.
Compare Another Pair
Related Comparisons
APYX vs DERM: Head-to-Head Comparison
This page compares Apyx Medical Corporation (APYX) and Journey Medical Corporation (DERM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.